What happened
Kolon Life Science updated its previously filed consolidated results for FY2025: revenue of US$143M (+29.5% year on year), operating profit of US$12M (from a loss a year earlier) and net income of US$17.1M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$143M |
|---|---|
| Revenue vs a year earlier | +29.5% |
| Operating profit | US$12M |
| Net income | US$17.1M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-05, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260305901297 → open original filing |
Versions of this filing
- 2026-02-11Original
- 2026-03-05Amendment 1 (this page)
Source: DART. Information only, not investment advice.